Cargando…

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations

BACKGROUND: The efficacy of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) patients harboring neurotrophin receptor kinase (NTRK) family mutations remains obscure. METHODS: The Zehir cohort from cBioPortal was used to analyze the mutations (MT) frequency of NTRK family in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shang, Xiaoling, Zhang, Wengang, Han, Wenfei, Xia, Handai, Liu, Ni, Wang, Xiuwen, Liu, Yanguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688060/ https://www.ncbi.nlm.nih.gov/pubmed/38031067 http://dx.doi.org/10.1186/s12890-023-02707-x

Ejemplares similares

CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma
por: Zhang, Wengang, et al.
Publicado: (2022)

Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
por: Xia, Handai, et al.
Publicado: (2022)

Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma
por: Zhang, Wengang, et al.
Publicado: (2022)

ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma
por: Zhang, Wengang, et al.
Publicado: (2022)

Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors
por: Chen, Qian, et al.
Publicado: (2022)

Predictive value of the prognostic nutritional index in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
por: Xia, Handai, et al.
Publicado: (2023)

Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer
por: Yang, Rui, et al.
Publicado: (2022)

Targeted paclitaxel‐octreotide conjugates inhibited the growth of paclitaxel‐resistant human non‐small cell lung cancer A549 cells in vitro
por: Liu, Yanguo, et al.
Publicado: (2021)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types
por: Shang, Xiaoling, et al.
Publicado: (2022)

Multi‐cohort analysis identifies somatic NTRK mutations as a biomarker for immune checkpoint inhibitor use in cutaneous melanoma
por: Yan, Junya, et al.
Publicado: (2023)

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
por: Jiang, Tingting, et al.
Publicado: (2021)

The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer
por: Qin, Haixia, et al.
Publicado: (2022)

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance
por: Liu, Fangfang, et al.
Publicado: (2022)

Association of ERCC family mutations with prognosis and immune checkpoint inhibitors response in multiple cancers
por: Chen, Chao, et al.
Publicado: (2023)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

MMR-deficiency and BRCA2/EGFR/NTRK mutations
por: Gokare, Prashanth, et al.
Publicado: (2017)

The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation
por: Jeong, Sun Young, et al.
Publicado: (2023)

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma
por: Li, Liu, et al.
Publicado: (2023)

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
por: Yamada, Tadaaki, et al.
Publicado: (2019)

Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis
por: Zhang, Rui, et al.
Publicado: (2021)

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
por: Somwar, Romel, et al.
Publicado: (2020)

Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy
por: Chatrath, Ajay, et al.
Publicado: (2021)

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
por: Moeckel, Camille, et al.
Publicado: (2023)

NTRK1/TrkA Activation Overrides the G(2)/M-Checkpoint upon Irradiation
por: Hassiepen, Christina, et al.
Publicado: (2021)

Novel NTRK1 mutations in Chinese patients with congenital insensitivity to pain with anhidrosis
por: Geng, Xingzhu, et al.
Publicado: (2018)

Expression of the neurotrophic tyrosine kinase receptors, ntrk1 and ntrk2a, precedes expression of other ntrk genes in embryonic zebrafish
por: Hahn, Katie, et al.
Publicado: (2020)

The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer
por: Zeng, Hao, et al.
Publicado: (2022)

Gut microbiome modulates efficacy of immune checkpoint inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
por: Wang, Yuekun, et al.
Publicado: (2020)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2022)

Novel Gross Deletion Mutations in NTRK1 Gene Associated With Congenital Insensitivity to Pain With Anhidrosis
por: Li, Lulu, et al.
Publicado: (2021)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Biomarkers for predicting the efficacy of immune checkpoint inhibitors
por: Wang, Chengji, et al.
Publicado: (2022)

The efficacy of immune checkpoint inhibitors in thoracic malignancies
por: Remon, Jordi, et al.
Publicado: (2021)

Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
por: Chong, Wei, et al.
Publicado: (2020)

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Li, Teng, et al.
Publicado: (2021)

Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Kim, Jong Yeob, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f0pifbcd6oj5tgobi7d4t7i7h6